<code id='13C1CBBB1F'></code><style id='13C1CBBB1F'></style>
    • <acronym id='13C1CBBB1F'></acronym>
      <center id='13C1CBBB1F'><center id='13C1CBBB1F'><tfoot id='13C1CBBB1F'></tfoot></center><abbr id='13C1CBBB1F'><dir id='13C1CBBB1F'><tfoot id='13C1CBBB1F'></tfoot><noframes id='13C1CBBB1F'>

    • <optgroup id='13C1CBBB1F'><strike id='13C1CBBB1F'><sup id='13C1CBBB1F'></sup></strike><code id='13C1CBBB1F'></code></optgroup>
        1. <b id='13C1CBBB1F'><label id='13C1CBBB1F'><select id='13C1CBBB1F'><dt id='13C1CBBB1F'><span id='13C1CBBB1F'></span></dt></select></label></b><u id='13C1CBBB1F'></u>
          <i id='13C1CBBB1F'><strike id='13C1CBBB1F'><tt id='13C1CBBB1F'><pre id='13C1CBBB1F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:hotspot    - browse:722
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge